3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Hemorrhage
12
Neoplasms
7
Leiomyoma
6
Breast Neoplasms
6
Thrombocytopenia
3
Postoperative Hemorrhage
3
Meningioma
3
Hematologic Neoplasms
3
Urinary Bladder Neoplasms
2
Seroma
2
Seizures
2
Prostatic Neoplasms
2
Myofibroma
2
Menorrhagia
2
Brain Neoplasms
2
Bone Neoplasms
2
Blood Loss, Surgical
2
Wrist Fractures
1
Urologic Diseases
1
Urinary Tract Infections
1
Urinary Retention
1
Thromboembolism
1
Stomach Neoplasms
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Skin Neoplasms
1
Sepsis
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Interventions
Cyclophosphamide
81
fludarabine phosphate
77
Peripheral Blood Stem Cell Transplantation
62
Mycophenolic Acid
55
Tacrolimus
54
Whole-Body Irradiation
52
Busulfan
51
Antilymphocyte Serum
45
Cyclosporine
41
fludarabine
36
Methotrexate
32
Filgrastim
32
Melphalan
30
Radiotherapy
25
Methylprednisolone
19
Cytarabine
17
Cord Blood Stem Cell Transplantation
17
Sirolimus
15
Azacitidine
15
Granulocyte Colony-Stimulating Factor
14
Alemtuzumab
14
thymoglobulin
13
Flow Cytometry
13
Etoposide
13
Cyclosporins
13
Specimen Handling
10
Biopsy
10
Thiotepa
9
Psychiatric Rehabilitation
9
Decitabine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Myeloproliferative Disorders
×
Tranexamic Acid
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled